Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study

Abstract: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least 2 prior treatment lines, but real-world data are scarce. In this retrospective, multicenter, multinational study, we evaluated the outcomes...

Full description

Saved in:
Bibliographic Details
Main Authors: Evgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, Meng Wang, Thomas Melchardt, Udo Holtick, Ulrike Bacher, Philipp Staber, Paolo Mazzeo, Corinna Leng, David Böckle, Alexander Hölscher, Joseph Kauer, Natalia Rotter, Vladan Vucinic, Jakob Rudzki, David Nachbaur, Veit Bücklein, Ulf Schnetzke, Isabelle Krämer, Kai Wille, Alexander Hasse, Bastian von Tresckow, Mathias Hänel, Christian Koenecke, Giuliano Filippini Velazquez, Andreas Viardot, Christoph Schmid, Lorenz Thurner, Dominik Wolf, Marion Subklewe, Martin Dreyling, Peter Dreger, Sascha Dietrich, Ulrich Keller, Ulrich Jäger, Richard Greil, Thomas Pabst, Georg Lenz, Björn Chapuy
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924007195
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items